Citation Impact
Citing Papers
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
2010 Standout
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
2009 Standout
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
2008 Standout
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Recombinant Human Erythropoietins and Cancer Patients: Updated Meta-Analysis of 57 Studies Including 9353 Patients
2006
Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis
2015
Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia
2008
Nanobody stabilization of G protein-coupled receptor conformational states
2011 StandoutNobel
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
1991 Standout
Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect
2016
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis
2007
Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody
1995
Neuroblastoma: biological insights into a clinical enigma
2003 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Coordinated regulation of myeloid cells by tumours
2012 Standout
Nasopharyngeal carcinoma
2019 Standout
Tumors establish resistance to immunotherapy by regulating Tregrecruitment via CCR4
2020
Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma
2011
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
Gemcitabine in transitional cell carcinoma of the urothelium
2003
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
2017 Standout
Myeloid-derived suppressor cells as regulators of the immune system
2009 Standout
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
2017 Standout
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Molecular mechanisms of cisplatin resistance
2011 Standout
Laparoscopic Photodynamic Diagnosis of Ovarian Cancer Using 5-Aminolevulinic Acid in a Rat Model
2002
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Glycans in cancer and inflammation — potential for therapeutics and diagnostics
2005 StandoutNobel
Epothilones in the treatment of cancer
2006
Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer
2008
Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review
2007
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
Prevention of Venous Thromboembolism
2004 Standout
Calmodulin as a Versatile Tag for Antibody Fragments
1995 StandoutNobel
Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer.
1990
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
2010 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Single domain camel antibodies: current status
2001
Neuroblastoma
2007 Standout
Prevention of Venous Thromboembolism
2008 Standout
A comparison between 111In-anti-E-selectin mAb and 99Tcm-labelled human non-specific immunoglobulin in radionuclide imaging of rheumatoid arthritis.
1997
Medical Treatment of Advanced Testicular Cancer
2008
Tumour localisation with a radioactively labelled reshaped human monoclonal antibody
1991
Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies.
1987
The follow-up of ovarian cancer
2003
Humanized antibodies
1993 StandoutNobel
New modalities in detection of recurrent ovarian cancer
2004
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.
1998
In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring
2009
Current Standards of Care in Small-Cell and Non-Small-Cell Lung Cancer
2001
Cancer of the Ovary
2004 Standout
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
2017 Standout
Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial
2012
Secretome Analysis of Multiple Pancreatic Cancer Cell Lines Reveals Perturbations of Key Functional Networks
2010
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
2001 Standout
Cancer Markers of the 1990s: Comparison of the New Generation of Markers Defined by Monoclonal Antibodies and Oncogene Probes to Prototypic Markers
1990
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
2006 Standout
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
2017 Standout
Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer
2006
Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma
2006
Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer
2009
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Intraepithelial CD8+tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
2005 Standout
Markers of Response for the Antiangiogenic Agent Bevacizumab
2013
Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function
2007
Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients.
1991
Growth Factors and Cancer
1991 StandoutScience
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
2010 Standout
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Development and validation of a predictive model for chemotherapy-associated thrombosis
2008 Standout
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
2016
Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer
2006
Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results
2002
Multiple Click-Selective tRNA Synthetases Expand Mammalian Cell-Specific Proteomics
2018 StandoutNobel
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
2005 Standout
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Works of D. Pectasides being referenced
An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
2001
The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients
2014
Gemcitabine and oxaliplatin (GEMOX) in patients withcisplatin-refractory germ cell tumors: a phase II study
2004
Diffuse Large Cell Lymphomas: Identification of Prognostic Factors and Validation of the International Non-Hodgkin’s Lymphoma Prognostic Index
1998
Combination chemotherapy with low doses of weekly Carboplatin and oral Etoposide in poor risk small cell lung cancer
1999
The combination of gemcitabine and carboplatin as first‐line treatment in patients with advanced urothelial carcinoma
2005
Comparison of docetaxel and docetaxel–irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial
2005
Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?
2006
Prevention of Anemia in Patients with Solid Tumors Receiving Platinum-Based Chemotherapy by Recombinant Human Erythropoietin (rHuEpo): A Prospective, Open Label, Randomized Trial by the Hellenic Cooperative Oncology Group
2003
Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial
2002
Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study
2003
Comparison of Two Different Doses of Ondansetron plus Dexamethasone in the Prophylaxis of Cisplatin-lnduced Emesis
1997
Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group
2001
Correlation of Abdominal Computed Tomography Scanning and Second-Look Operation Findings in Ovarian Cancer Patients
1991
Pancreatic cancer: Current and future treatment strategies
2009
Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab
2011
Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms.
1986
A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin.
2008
Gemcitabine (G) vs gemcitabine-carboplatin (GCB) for patients with advanced non-small cell lung cancer (NSCLC) and PS:2. A prospective randomized phase II study of the Hellenic Co-Operative Oncology Group
2004
Serum Levels of C-Myc and C-Ras Oncogene Products in Normal Subjects and in Patients with Neoplastic and Non Neoplastic Conditions
1986
Kit expression in male germ cell tumors.
2007
Gemcitabine (G) vs gemcitabine-carboplatin (GCB) for patients with advanced non-small cell lung cancer (NSCLC) and PS:2. A prospective randomized phase II study of the Hellenic Co-Operative Oncology Group
2004